Cargando…
Short Synthesis of Molnupiravir (EIDD-2801) via a Thionated Uridine Intermediate
[Image: see text] Molnupiravir (MK-4482, EIDD-2801) is an experimental drug that has been demonstrated to be effective for the treatment of COVID-19 in human clinical trials. Herein, we report a concise synthesis of the drug via a novel thionated derivative that relies on one-pot methodologies, thus...
Autores principales: | Dey, Raghunath, Nayak, Sourav, Das, Parthasarathi, Yadav, Somnath |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552467/ https://www.ncbi.nlm.nih.gov/pubmed/34723033 http://dx.doi.org/10.1021/acsomega.1c04550 |
Ejemplares similares
-
A High‐Yielding Synthesis of EIDD‐2801 from Uridine
por: Steiner, Alexander, et al.
Publicado: (2020) -
Progress Toward a Large-Scale Synthesis of Molnupiravir
(MK-4482, EIDD-2801) from Cytidine
por: Ahlqvist, Grace P., et al.
Publicado: (2021) -
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
por: Johnson, Dylan M., et al.
Publicado: (2023) -
Conversion of N-acyl amidines to amidoximes: a convenient synthetic approach to molnupiravir (EIDD-2801) from ribose
por: Ahmed, Ajaz, et al.
Publicado: (2021) -
Correction: Conversion of N-acyl amidines to amidoximes: a convenient synthetic approach to molnupiravir (EIDD-2801) from ribose
por: Ahmed, Ajaz, et al.
Publicado: (2022)